



Estradiol (E2) Test System

Product Code: 4925-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Estradiol Concentration in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Colorimetric

2.0 SUMMARY AND EXPLANATION OF THE TEST

Measurement of estradiol in serum or plasma is considered to be the most reliable way to assess its rate of production.

Estradiol (17 β -estradiol) is a steroid hormone (molecular weight of 272.3 daltons), which circulates predominantly protein-bound. In addition to estradiol, other natural steroidal estrogens include estrone, estriol and their metabolites. Natural estrogens are hormones secreted principally by the ovarian follicles and also by the adrenals, corpus luteum, and placenta and, in males, by the testes. Exogenous estrogens (natural or synthetic) elicit, to varying degrees, all the pharmacologic responses usually produced by endogenous estrogens.

Estrogenic hormones are secreted at varying rates during the menstrual cycle throughout the period of ovarian activity. During pregnancy, the placenta becomes the main source of estrogens. At menopause, ovarian secretion of estrogens declines at varying rates. The gonadotropins of the anterior pituitary regulate secretion of the ovarian hormones, estradiol and progesterone; hypothalamic control of pituitary gonadotropin production is in turn regulated by plasma concentrations of the estrogens and progesterone. This complex feedback system results in the cyclic phenomenon of ovulation and menstruation.

Estradiol determinations have proved of value in a variety of contexts, including the investigation of precocious puberty in girls and gynecomastia in men. Its principal uses have been in the differential diagnosis of amenorrhea and in the monitoring of ovulation induction.


This kit uses a specific anti-estradiol antibody, and does not require prior sample extraction of serum or plasma. Cross-reactivity to other naturally occurring and structurally related steroids is low.

The employment of several serum references of known estradiol concentration permits construction of a graph of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with estradiol concentration.


3.0 PRINCIPLE

Delayed Competitive Enzyme Immunoassay (TYPE 9):


The essential reagents required for an enzyme immunoassay include antibody, enzyme-antigen conjugate and native antigen. Upon mixing the biotinylated antibody with a serum containing the antigen, a reaction results between the antigen and the antibody. The interaction is illustrated by the following equation:



After a short incubation, the enzyme conjugate is added (This delayed addition permits an increase in sensitivity for low concentration samples). Upon the addition of the enzyme conjugate, competition reaction results between the enzyme analog and the antigen in the sample for a limited number of antibody binding sites (not consumed in the first incubation).



A simultaneous reaction between the biotin attached to the antibody and the streptavidin immobilized on the microwell occurs. This effects the separation of the antibody bound fraction after decantation or aspiration.



The enzyme activity in the antibody bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

Materials Provided

A. Estradiol Calibrators – 1ml/vial - Icons A-G

Seven (7) vials of serum reference for estradiol at concentrations of 0 (A), 20 (B), 100 (C), 250 (D), 500 (E), 1500 (F) and 3000 (G) in pg/ml. Store at 2-8°C. A preservative has been added. The calibrators can be expressed in molar concentrations (pM/L) by multiplying by 3.67. For example: 1pg/ml x 3.67= 3.67 pM/L

B. Estradiol Enzyme Reagent – 6.0 ml/vial

One (1) vial of Estradiol (Analog)-horseradish peroxidase (HRP) conjugate in a protein-stabilizing matrix red with dye. Store at 2-8°C.

C. Estradiol Biotin Reagent – 6.0 ml - Icon

One (1) bottle of reagent contains anti-estradiol biotinylated purified rabbit IgG conjugate in buffer, green dye and preservative. Store at 2-8°C.

D. Streptavidin Coated Plate – 96 wells -Icon

One 96-well microplate coated with 1.0 µg/ml streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

E. Wash Solution Concentrate – 20ml/vial - Icon

One (1) vial contains a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

F. Substrate Reagent – 12ml/vial - Icon

One (1) vial contains tetramethylbenzidine (TMB) and hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C.

G. Stop Solution – 8ml/vial - Icon

One (1) vial contains a strong acid (0.5M H₂SO₄). Store at 2-8°C.

H. Product Instructions

Note 1: Do not use reagents beyond the kit expiration date.

Note 2: Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on label.**

Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

- Pipette capable of delivering 0.025ml (25µl) and 0.050ml (50µl) with a precision of better than 1.5%.
- Dispenser(s) for repetitive deliveries of 0.100ml (100µl) and 0.350ml (350µl) volumes with a precision of better than 1.5%.
- Microplate washer or a squeeze bottle (optional).

- Absorbent Paper for blotting the microplate wells.
- Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- Plastic wrap or microplate cover for incubation steps.
- Vacuum aspirator (optional) for wash steps.
- Timer.
- Quality control materials.

5.0 PRECAUTIONS

For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe Disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum or heparinized plasma in type, and taken with the usual precautions in the collection of venipuncture samples. For accurate comparison to establish normal values, a fasting morning serum sample should be obtained. The blood should be collected in a redtop (with or without gel additives) venipuncture tube(s) or for plasma use evacuated tube(s) containing heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

1. Wash Buffer

Dilute contents of wash solution to 1000ml with distilled or deionized water in a suitable storage container. Diluted buffer can be stored at 2-30°C for up to 60 days.

Note: Do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C).

****Test Procedure should be performed by a skilled individual or trained professional****

- Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- Pipette 0.025 ml (25 µL) of the appropriate serum reference calibrator, control or specimen into the assigned well.
- Add 0.050 ml (50µl) of the Estradiol Biotin Reagent to all wells.
- Swirl the microplate gently for 20-30 seconds to mix.
- Cover and incubate for 30 minutes at room temperature.
- Add 0.050 ml (50µl) of Estradiol Enzyme Reagent to all wells. **Add directly on top the reagents dispensed in the wells.**
- Swirl the microplate gently for 20-30 seconds to mix.
- Cover and incubate for 90 minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of substrate solution to all wells. **Always add reagents in the same order to minimize reaction time differences between wells.**
- DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
- Incubate at room temperature for twenty (20) minutes.
- Add 0.050ml (50µl) of stop solution to each well and gently mix for 10-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells.**
- Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm). **The results should be read within fifteen (15) minutes of adding the stop solution.**

Note: Dilute the samples suspected of concentrations higher than 3000pg/ml 1:5 and 1:10 with estradiol '0' pg/ml calibrator or male patient serum pools with a known low value for estradiol.

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of estradiol in unknown specimens.


- Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- Plot the absorbance for each duplicate serum reference versus the corresponding estradiol concentration in pg/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
- Connect the points with a best-fit curve.
- To determine the concentration of estradiol for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in pg/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.202) intersects the dose response curve at (160pg/ml) estradiol concentration (See Figure 1).

Note: Computer data reduction software designed for ELISA assay may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

EXAMPLE 1

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (pg/ml)
Cal A	A1	2.268	2.256	0
	B1	2.244		
Cal B	C1	1.839	1.849	20
	D1	1.860		
Cal C	E1	1.409	1.426	100
	F1	1.443		
Cal D	G1	1.017	1.003	250
	H1	0.989		
Cal E	A2	0.698	0.723	500
	B2	0.748		
Cal F	C2	0.480	0.487	1500
	D2	0.493		
Cal G	E2	0.390	0.388	3000
	F2	0.385		
Pat# 1	G2	1.202	1.202	160
	H2	1.203		

*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay.



Note: Multiply the horizontal values by 1000 to convert into pg/ml.

11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

- The absorbance (OD) of calibrator 0 pg/ml should be ≥ 1.3
- Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

- It is important that the time of reaction in each well is held constant to achieve reproducible results.
- Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
- If more than one (1) plate is used, it is recommended to repeat the dose response curve.
- The addition of substrate solution initiates a kinetic reaction, terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
- Plate readers measure vertically. Do not touch the bottom of the wells.
- Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- Use components from the same lot. No intermixing of reagents from different batches.
- Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
- All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper usage.

- It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

- Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
- Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
- The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscatto LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988;34:27-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
- For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
- If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.

13.0 EXPECTED RANGES OF VALUES

In agreement with established reference intervals for a "normal" adult population and females during gestation the expected ranges for the Estradiol AccuBind® ELISA Test System are detailed in Table 1.

	Median	Range
Females		
Follicular Phase	48	9-175
Luteal Phase	103	44-196
Periovulatory	209	107-281
Treated Menopausal	122	42-289
Untreated Menopausal	7.3	ND-20
Oral Contraceptives	13	ND-103
Males	19	4-94

During pregnancy the Estradiol serum levels rise rapidly till the end of third trimester.¹⁵

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal" persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within and between assay precision of the estradiol AccuBind® Microplate ELISA Test System were determined by analyses on three different levels of pool control sera. The number, mean values, standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

Sample	N	X	σ	C.V.
Low	20	81.9	8.1	9.9%
Normal	20	242.7	20.5	8.5%
High	20	423.7	7.5	7.5%

Sample	N	X	σ	C.V.
Low	20	106.1	5.1	4.8%
Normal	20	261.5	10.0	3.8%
High	20	436.7	13.5	8.2%

*As measured in ten experiments in duplicate over a ten day period.

14.2 Sensitivity

The estradiol AccuBind® EIA Test System has a sensitivity of 8.2 pg/ml. The sensitivity was ascertained by determining the variability of the 0 pg/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose.

14.3 Accuracy

The Estradiol AccuBind® ELISA Test System was compared with a reference method. Biological specimens from low, normal and relatively high estradiol level populations were used (The values ranged from 10 pg/ml – 4300 pg/ml). The total number of such specimens was 65. The least square regression equation and the correlation coefficient were computed for this estradiol EIA in comparison with the reference method. The data obtained is displayed in Table 4.

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind (y)	336.8	$y = 36.50 + 1.023(x)$	0.989
Reference (X)	293.4		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4 Specificity

The % cross reactivity of the estradiol antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of estradiol needed to displace the same amount of labeled analog.

Substance	Cross Reactivity
Androstenedione	0.0003
Dihydrotestosterone	0.0008
Cortisone	<0.0001
Corticosterone	<0.0001
Cortisol	0.0004
Estrilol	<0.0001
DHEA sulfate	<0.0001
Estradiol	<0.0001
Estrone	<0.0001
Testosterone	<0.0001

15.0 REFERENCES

- Abraham GE. The application of natural steroid radioimmunoassay to gynecologic endocrinology. In: Abraham GE, editor. *Radioassay Systems in Clinical Endocrinology*. Basel: Marcel Dekker.; 475-529 (1981).
- Batzer F. "Hormonal evaluation of early pregnancy", *Fertility Sterility*, 34:1-13 (1980).
- Bauman J. "Basal body temperature: unreliable method of ovulation detection", *Fertility Sterility*, 36:729-33, (1981).
- Bergquist C, Nilius SJ, Wide L "Human gonadotropin therapy: Serum estradiol and progesterone patterns during conceptual cycles", *Fertility Sterility*, 39:761-65 (1983).
- Gautray JP, et al, "Clinical investigation of the menstrual cycle: clinical, endometrial and endocrine aspects of luteal defects", *Fertility Sterility*, 35:296-303 (1981).
- Hensleigh PA, Fainstat T, "Corpus luteum dysfunction: serum progesterone levels in diagnosis and assessment of therapy for recurrent and threatened abortion", *Fertility Sterility*, 32:396-9, (1979)
- Hernandez JL, et al, "Direct evidence of luteal insufficiency in women with habitual abortion", *Obstetric Gynecology*, 49:705-8, (1977).
- Goldstein D, et al, "Correlation between Estradiol and Progesterone in cycles with luteal phase deficiency", *Fertility Sterility*, 37:348-54 (1982).

- Klopper A, Fuchs F. Progesteragens. In: Fuchs F, Klopper A, editors. *Endocrinology of Pregnancy*. Hagerstown: Harper & Row, 99-122 (1977).
- Lehmann F, Bettendorf G, "The endocrine shift from a normal cycle to anovulation", In: Insler V, Bettendorf G, editors. *Advances in Diagnosis and Treatment of Infertility*. Amsterdam: Elsevier/North Holland, 105 -13 (1981).
- March CM. Luteal phase defects. In: Mishell DR, Davajan V, editors. *Reproductive Endocrinology, Infertility and Contraception*. Philadelphia: F. A. Davis Company, 1979: 469-76.
- March CM, Goebelsmann U, Nakamura RM, Mishell Dr. Roles of estradiol and progesterone in eliciting the midcycle luteinizing hormone and follicle stimulating hormone surges. *J Clin Endocrinol Metab*, 49:507-13 (1979).
- BIO-ED slide/seminar educational program. Rochester: Bioeducational Publications, 1981.
- Radwanska E, et al, "Plasma progesterone levels in normal and abnormal early human pregnancy", *Fertility Sterility* 30:398-402 (1978).
- Tietz, *Textbook of clinical chemistry*, 2nd ed. Philadelphia: W.B. Saunders, (1994).

Revision: 5 Date: 2019-Jul-16 DCO: 1353
MP4925 Product Code: 4925-300

Size	96(A)	192(B)	
Reagent (fill)	A)	1ml set	1ml set
	B)	1 (6ml)	2 (6ml)
	C)	1 (6ml)	2 (6ml)
	D)	1 plate	2 plates
	E)	1 (20ml)	1 (20ml)
	F)	1 (12ml)	2 (12ml)
	G)	1 (8ml)	2 (8ml)

For Orders and Inquires, please contact

Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: Info@monobind.com
Fax: +1 949.951.3539 Fax: www.monobind.com



Please visit our website to learn more about our products and services.

**Glossary of Symbols
(EN 980/ISO 15223)**

